Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Crofelemer
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Jaguar Gets Regulatory Approval for Crofelemer in SBS-IF Rare Disease Study
Details : Mytesi (crofelemer) is a plant-based drug extracted & purified from the red bark sap. It is being developed for short bowel syndrome with intestinal failure.
Product Name : Mytesi
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 19, 2025
Lead Product(s) : Crofelemer
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : NP-300
Therapeutic Area : Infections and Infectious Diseases
Study Phase : IND Enabling
Sponsor : Streeterville
Deal Size : Undisclosed
Deal Type : Collaboration
Jaguar Health Extends Collaboration for Tropical Disease Review Voucher
Details : The collaboration aims to advance the clinical development of NP-300 drug product candidate for the symptomatic relief of diarrhea and dehydration in cholera patients.
Product Name : NP-300
Product Type : Plant Extract/Herbal
Upfront Cash : Undisclosed
February 18, 2025
Lead Product(s) : NP-300
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : IND Enabling
Sponsor : Streeterville
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Crofelemer
Therapeutic Area : Gastroenterology
Study Phase : Phase I
Sponsor : SPRIM Global investments
Deal Size : $58.8 million
Deal Type : Private Placement
Details : The company's initial focus is on clinical development and future registration in Europe of Mytesi (crofelemer) for two debilitating rare disease target indications: short bowel syndrome (SBS) and congenital diarrheal disorders (CDD) with intestinal fail...
Product Name : Mytesi
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 02, 2023
Lead Product(s) : Crofelemer
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I
Sponsor : SPRIM Global investments
Deal Size : $58.8 million
Deal Type : Private Placement